<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic primary mitral regurgitation: General management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic primary mitral regurgitation: General management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic primary mitral regurgitation: General management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vuyisile T Nkomo, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary mitral regurgitation (MR) is caused by a primary abnormality of one or more components of the valve apparatus (leaflets, chordae tendineae, papillary muscles, annulus), in contrast to secondary MR, which is caused by alterations in left ventricular (LV) and/or atrial geometry and function  (<a class="graphic graphic_table graphicRef64974" href="/z/d/graphic/64974.html" rel="external">table 1</a>). Identification of the cause and type (primary or secondary) of MR is required for appropriate management of MR as well as any associated conditions.</p><p>Mitral valve prolapse is the most common cause of chronic primary MR in resource-abundant countries. Rheumatic heart disease is a prominent cause of primary MR in resource-limited countries (particularly during the first two decades of life), but it is an uncommon cause of MR in resource-abundant countries. (See  <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease", section on 'Mitral regurgitation'</a>.)</p><p>Other causes of primary MR are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Etiology'</a>.)</p><p>This topic will discuss general management for patients with chronic primary MR. Indications for intervention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p>The pathophysiology, natural history, diagnosis, and evaluation of chronic MR, and the management of chronic secondary MR, are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8163.html" rel="external">"Pathophysiology and natural history of chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/8162.html" rel="external">"Natural history of chronic mitral regurgitation caused by mitral valve prolapse and flail mitral leaflet"</a> and  <a class="medical medical_review" href="/z/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/102361.html" rel="external">"Chronic secondary mitral regurgitation: General management and prognosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Following initial evaluation of chronic primary MR, including staging and identification of its cause, serial monitoring and restaging is required as clinical findings evolve. Staging is based upon symptoms, valve anatomy, valve hemodynamics (severity of MR), and hemodynamic consequences of MR as reflected by left atrial size, LV size and function, and pulmonary artery pressure  (<a class="graphic graphic_table graphicRef95916" href="/z/d/graphic/95916.html" rel="external">table 2</a>). MR severity should be formally quantified, as color Doppler appearance may be misleading. Concurrent valve disease, including tricuspid valve prolapse and tricuspid regurgitation, should also be monitored. (See  <a class="medical medical_review" href="/z/d/html/8119.html" rel="external">"Etiology, clinical features, and evaluation of tricuspid regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/5292.html" rel="external">"Echocardiographic evaluation of the tricuspid valve"</a>.)</p><p>A goal of monitoring is to identify changes (which can occur with or without reported symptoms) for optimal timing of intervention.</p><p>We agree with the following recommendations for clinical and transthoracic echocardiographic (TTE) monitoring in asymptomatic patients with primary mitral valve disease and chronic MR in the 2020 American College of Cardiology/American Heart Association guidelines [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Annual visits</strong> – Follow-up for patients with primary mitral valve disease and moderate to severe MR includes at least an annual history and physical examination. For individuals with mild MR, frequency of follow-up is based on the type and severity of mitral leaflet disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiography</strong> – Serial TTE is performed to assess the severity of valve disease, LV size, LV ejection fraction (LVEF), and LV end-systolic dimension. TTE interpretation should include careful comparison with prior TTE studies. The frequency of recommended follow-up varies with the severity of MR:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild MR</strong> – For patients with primary mitral valve disease and mild MR and no evidence of LV enlargement, LV dysfunction, or pulmonary hypertension, echocardiography every three to five years is appropriate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate MR</strong> – Patients with primary mitral valve disease and moderate MR should undergo echocardiography every one to two years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe MR</strong> – Patients with severe MR should be seen every 6 to 12 months (sooner if symptoms occur) with a repeat TTE. The six-month interval is preferred if stability has not been documented, if there is evidence of progressive LV dilation, reduction in LV systolic function, or increase in pulmonary pressure, or if measurements are approaching values used in an indication for mitral valve surgery.</p><p></p><p class="bulletIndent2">While LV systolic function is most commonly assessed by LVEF, global longitudinal strain may be a helpful adjunct in patients with asymptomatic severe MR, as strain is a more sensitive indicator of LV systolic dysfunction in patients with MR, although not yet included in guidelines for timing of intervention [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function", section on 'Other measures'</a>.)</p><p></p><p>In addition, TTE should be performed in patients with MR with a change in symptoms (eg, dyspnea or reduced exercise tolerance) or signs, or new onset of atrial fibrillation [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H615309715"><span class="h1">ADJUNCTIVE TESTING</span></p><p class="headingAnchor" id="H610558170"><span class="h2">Natriuretic peptide levels</span><span class="headingEndMark"> — </span>Natriuretic peptide (B-type natriuretic peptide [BNP] or N-terminal pro-BNP [NT-proBNP]) level measurement is not routinely required but may be helpful in settings in which clinical data are conflicting or uncertain [<a href="#rid1">1,2</a>]. As an example, natriuretic peptide testing may be a helpful adjunct in asymptomatic patients with severe MR.</p><p>Studies suggest that serum BNP may have prognostic value in patients with chronic primary MR [<a href="#rid3">3</a>]. As an example, a report evaluated 124 patients with chronic MR, 94 with mitral valve prolapse; almost all patients were asymptomatic or had only a mild limitation in physical activity and the mean LVEF was 69 percent [<a href="#rid4">4</a>]. Serum BNP values ≥31 pg/mL predicted lower five-year survival (72 versus 96 percent). BNP was independently predictive of mortality with adjustment for age, sex, functional class, MR severity, and LVEF. Thus, BNP level reflected the clinical consequences of MR rather than the severity of MR. Similarly, a study of 135 asymptomatic patients with moderate to severe primary MR and preserved LVEF found that BNP was an independent predictor of cardiac events [<a href="#rid5">5</a>]. Observational studies have also suggested that patients with MR with elevated BNP or NT-proBNP levels may face increased risk of adverse outcomes following mitral valve surgery [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H361174791"><span class="h2">Transesophageal echocardiography</span><span class="headingEndMark"> — </span>Transesophageal echocardiography (TEE) is <strong>not</strong> indicated for follow-up of most patients. TEE is indicated when noninvasive imaging fails to determine the severity or cause of MR [<a href="#rid1">1</a>]. TEE also has a role in preoperative and intraoperative evaluation for mitral valve surgery to assess valve anatomy and help guide repair.</p><p class="headingAnchor" id="H615309722"><span class="h2">Exercise testing</span><span class="headingEndMark"> — </span>Hemodynamic exercise testing (with Doppler echocardiography, cardiac catheterization, or cardiopulmonary exercise testing) is not required for monitoring of most patients with chronic primary MR but may be helpful in certain settings [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>If it is unclear whether there is any exercise limitation by clinical history, exercise stress testing may add objective evidence about symptoms and a change in exercise tolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptoms that are greater than expected for the degree of MR at rest or for patients with borderline echocardiographic findings [<a href="#rid8">8</a>], exercise echocardiography including measurement of MR severity and pulmonary artery pressure during exercise may be helpful. Results of exercise echocardiography may have prognostic value in asymptomatic patients with moderate or severe chronic primary MR [<a href="#rid9">9-11</a>].</p><p></p><p class="headingAnchor" id="H442892522"><span class="h2">Cardiovascular magnetic resonance imaging</span><span class="headingEndMark"> — </span>Cardiovascular magnetic resonance imaging is not routinely indicated for monitoring of MR but is indicated when echocardiography is not adequate to assess MR severity or left and right ventricular volumes and function [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Regurgitant valve disease'</a>.)</p><p class="headingAnchor" id="H805744110"><span class="h2">Coronary angiography</span><span class="headingEndMark"> — </span>Many patients requiring surgery for chronic primary MR also have significant coronary artery disease. The prevalence of coronary artery disease (CAD) was assessed by a study of 722 patients (67 percent men, mean age 61 years) with primary MR who did not have a history of myocardial infarction, ischemic electrocardiographic changes, or angina [<a href="#rid12">12</a>]. Routine coronary angiography identified obstructive (≥50 percent) coronary lesions in one or more major vessels in 19 percent of patients.</p><p>Coronary angiography is recommended for hemodynamically stable patients who are planning to undergo valve surgery and have or are suspected of having CAD [<a href="#rid1">1,2</a>]. Individuals with coronary risk factors include men &gt;40 years of age and postmenopausal women. For patients with low to intermediate pretest probability of CAD, contrast-enhanced coronary computed tomographic angiography is an option to exclude the presence of significant obstructive CAD [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/5308.html" rel="external">"Cardiac imaging with computed tomography and magnetic resonance in the adult"</a>.)</p><p>Obstructive coronary lesions are generally revascularized at the time of mitral valve surgery, since concurrent bypass surgery typically adds little morbidity or mortality to the procedure. (See  <a class="medical medical_review" href="/z/d/html/140775.html" rel="external">"Chronic primary mitral regurgitation: Choice of intervention", section on 'Concurrent procedures'</a>.)</p><p class="headingAnchor" id="H1231502425"><span class="h1">GENERAL MANAGEMENT</span><span class="headingEndMark"> — </span>There is a limited role for medical management in patients with chronic primary MR, since valve intervention is required to address the primary process. The approach to management presented here is in general agreement with 2020 American College of Cardiology/American Heart Association (ACC/AHA) valve guidelines and 2021 European Society of Cardiology valve guidelines [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H989530314"><span class="h2">No routine vasodilator therapy</span><span class="headingEndMark"> — </span>Given lack of evidence of efficacy, vasodilators are <strong>not</strong> indicated for use in normotensive asymptomatic patients with chronic primary MR and normal systolic function [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H3958580528"><span class="h2">Treatment of heart failure</span><span class="headingEndMark"> — </span>Symptomatic patients with chronic primary MR (stage D) and LVEF &lt;60 percent who are awaiting valve surgery or who are not candidates for valve surgery are treated with standard evidence-based medical therapy for heart failure with reduced ejection fraction (HFrEF), which is also suggested for patients with heart failure with mildly reduced ejection fraction (HFmrEF; LVEF 41 to 49 percent). (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/117708.html" rel="external">"Treatment and prognosis of heart failure with mildly reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/117708.html" rel="external">"Treatment and prognosis of heart failure with mildly reduced ejection fraction", section on 'Therapy for mildly reduced ejection fraction'</a>.)</p><p>Medical therapy for symptomatic MR with LVEF &lt;60 percent is largely based on evidence in patients with HFrEF or HFmrEF [<a href="#rid1">1</a>]. Although LVEF values in the range of 50 to 60 percent are considered to be in a low-normal range in the general population without MR, patients with chronic primary MR and a low-normal LVEF have depressed LV intrinsic contractility, which is associated with suboptimal outcomes after otherwise successful corrective mitral surgery [<a href="#rid13">13,14</a>]. Scant evidence is available on HF therapy in patients with primary MR. Limited evidence on beta blocker therapy in patients with MR suggests a possible benefit. A preliminary trial randomly assigned 38 asymptomatic adults with moderate to severe MR to placebo or beta-1 blockade (with extended-release <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>) for two years [<a href="#rid15">15</a>]. LVEF and LV early diastolic filling rate improved with beta blocker therapy. A retrospective study of 895 patients with severe MR and normal LVEF found that beta blocker use was associated with a lower mortality rate [<a href="#rid16">16</a>], but this finding is not sufficient to establish the efficacy of beta blocker therapy.</p><p class="headingAnchor" id="H1508255006"><span class="h2">Intervention</span><span class="headingEndMark"> — </span>Management of primary MR is directed towards optimal timing of intervention with surgical mitral valve repair or replacement, as discussed separately. Transcatheter mitral valve repair is an option for selected severely symptomatic patients who are not surgical candidates. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p class="headingAnchor" id="H68156417"><span class="h2">Endocarditis prophylaxis</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis is <strong>not</strong> indicated for patients with native mitral valve disease (in the absence of history of infective endocarditis) undergoing dental or oral procedures [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a> and  <a class="medical medical_review" href="/z/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management", section on 'Infective endocarditis'</a>.)</p><p class="headingAnchor" id="H3140521179"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>Exercise has a variable effect on the regurgitant fraction in patients with chronic MR [<a href="#rid17">17</a>]. The reduction in systemic vascular resistance may result in no change or a mild reduction in the regurgitant fraction. On the other hand, an elevation in blood pressure or heart rate can lead to an increase in regurgitant volume and pulmonary capillary pressure.</p><p>We agree with the following recommendations for athletes with MR modified from the 2015 AHA/ACC scientific statement for competitive athletes with valvular heart disease [<a href="#rid17">17</a>]  (<a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Athletes with MR should be evaluated annually by physical examination, echocardiography, and exercise stress testing to determine whether sport participation can continue.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exercise testing to at least the level of activity achieved in competition and training is useful to confirm asymptomatic status in patients with MR.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Estimation of pulmonary artery systolic pressure during exercise by Doppler echocardiography can be helpful, particularly in athletes with significant MR. This evaluation is used to determine whether sport participation can continue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes in sinus rhythm with mild to moderate MR, normal LV function, and normal pulmonary artery pressure can participate in all competitive sports.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is reasonable for athletes with moderate MR in sinus rhythm with normal LV systolic function at rest (stage B) and mild LV enlargement (compatible with that resulting solely from athletic training; LV end-diastolic dimension [LVEDD] &lt;60 mm or &lt;35.3 mm/m<sup>2</sup> in males or &lt;40 mm/m<sup>2</sup> in females) to participate in all competitive sports.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes with asymptomatic severe MR in sinus rhythm with normal LV systolic function at rest and mild LV enlargement (compatible with that resulting solely from athletic training; LVEDD &lt;60 mm or &lt;35.3 mm/m<sup>2</sup> in males or &lt;40 mm/m<sup>2</sup> in females [stage C1]) can participate in low-intensity and some moderate-intensity sports (classes IA, IIA, and IB).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes with MR and definite LV enlargement (LVEDD ≥65 mm or ≥35.3 mm/m<sup>2</sup> in males or ≥40 mm/m<sup>2</sup> in females), pulmonary hypertension, or any degree of LV systolic dysfunction at rest (LVEF ≤60 percent or LVEDD ≥40 mm [stage C2]) should not participate in any competitive sports, with the possible exception of low-intensity class IA sports.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Athletes with a history of atrial fibrillation who are receiving long-term anticoagulation should not engage in sports involving risk of bodily contact  (<a class="graphic graphic_table graphicRef105803" href="/z/d/graphic/105803.html" rel="external">table 3</a>).</p><p></p><p>Exercise following mitral valve replacement or repair is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8134.html" rel="external">"Overview of the management of patients with prosthetic heart valves", section on 'Exercise recommendations'</a>.)</p><p class="headingAnchor" id="H569083445"><span class="h1">CAUSE-SPECIFIC MANAGEMENT</span><span class="headingEndMark"> — </span>Additional management considerations vary depending upon the cause of primary MR.</p><p class="headingAnchor" id="H3599654793"><span class="h2">Management for mitral valve prolapse</span><span class="headingEndMark"> — </span>Management of mitral valve prolapse includes assessment and management of concurrent tricuspid valve prolapse and arrhythmic risk, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management"</a>.)</p><p class="headingAnchor" id="H4243960902"><span class="h2">Management of rheumatic heart disease</span><span class="headingEndMark"> — </span>Management of rheumatic heart disease is discussed separately. For patients with rheumatic heart disease, long-term prophylaxis against rheumatic fever is recommended according to standard guidelines. (See  <a class="medical medical_review" href="/z/d/html/3175.html" rel="external">"Acute rheumatic fever: Treatment and prevention", section on 'Secondary prevention (antibiotic prophylaxis)'</a>.)</p><p class="headingAnchor" id="H50738829"><span class="h1">CONCURRENT CONDITIONS</span><span class="headingEndMark"> — </span>Patients with primary MR frequently have concurrent conditions that require treatment.</p><p class="headingAnchor" id="H1289703032"><span class="h2">Treatment of hypertension</span><span class="headingEndMark"> — </span>General recommendations for cardiovascular risk assessment and modification apply to patients with primary MR, including identification and management of hypertension, if present. Patients with chronic primary MR and concomitant hypertension should receive standard antihypertensive therapy to reduce the morbidity and mortality associated with hypertension [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p class="headingAnchor" id="H2519885821"><span class="h2">Conditions requiring concurrent intervention</span><span class="headingEndMark"> — </span>Some conditions that occur commonly in patients with primary MR may require intervention at the time of mitral valve intervention. These include coronary artery disease, atrial fibrillation, and concurrent valve disease (eg, tricuspid regurgitation). These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8138.html" rel="external">"Surgical procedures for severe chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/8145.html" rel="external">"Management and prognosis of tricuspid regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation"</a>.)</p><p class="headingAnchor" id="H3695165921"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H22402044"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15754.html" rel="external">"Patient education: Mitral regurgitation (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3437.html" rel="external">"Patient education: Mitral regurgitation (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5520719"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Primary mitral regurgitation (MR) is caused by a primary abnormality of one or more components of the valve apparatus (leaflets, chordae tendineae, papillary muscles, annulus). Mitral valve prolapse is the most common cause of chronic primary MR in resource-abundant countries. Rheumatic heart disease is a prominent cause of primary MR in resource-limited countries (particularly during the first two decades of life), but it is an uncommon cause of MR in resource-abundant countries. (See  <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease", section on 'Mitral regurgitation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients with significant mitral valve disease and chronic primary MR require routine clinical and echocardiographic monitoring. Valve disease stage is based upon symptoms, valve anatomy, valve hemodynamics (severity of MR), and hemodynamic consequences of MR as reflected by left atrial size, left ventricular (LV) size and function, and pulmonary artery pressure  (<a class="graphic graphic_table graphicRef95916" href="/z/d/graphic/95916.html" rel="external">table 2</a>). MR severity should be quantified when possible because color Doppler appearance often is misleading. The frequency of transthoracic echocardiographic (TTE) monitoring in patients with MR varies depending upon clinical findings and the severity of MR. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive testing</strong> – When the severity of MR is uncertain by TTE, transesophageal echocardiography or cardiovascular magnetic resonance imaging may be helpful. (See <a class="local">'Adjunctive testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of heart failure</strong> – Symptomatic patients with chronic primary MR (stage D) and LV ejection fraction (LVEF) &lt;60 percent who are awaiting valve surgery or who are not candidates for valve surgery are treated with standard evidence-based medical therapy for heart failure with reduced ejection fraction (HFrEF). (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/117708.html" rel="external">"Treatment and prognosis of heart failure with mildly reduced ejection fraction", section on 'Therapy for mildly reduced ejection fraction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocarditis prophylaxis</strong> – Antibiotic prophylaxis is <strong>not</strong> indicated for patients with mitral valve disease (in the absence of prosthetic valve replacement or history of infective endocarditis). This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cause-specific management </strong>– Patients with mitral valve prolapse require assessment for concurrent tricuspid valve disease and arrhythmic risk. Patients with rheumatic heart disease are treated with prophylaxis against rheumatic fever. (See  <a class="medical medical_review" href="/z/d/html/8169.html" rel="external">"Mitral valve prolapse: Overview of complications and their management"</a> and  <a class="medical medical_review" href="/z/d/html/114019.html" rel="external">"Management and prevention of rheumatic heart disease", section on 'Secondary prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concurrent conditions</strong> – Patients with mitral valve prolapse commonly have concurrent conditions such as hypertension, coronary artery disease, and atrial fibrillation that require treatment. (See <a class="local">'Concurrent conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intervention</strong> - Indications for mitral valve intervention (surgical repair or replacement or transcatheter repair) and the timing and optimal choice of intervention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="headingAnchor" id="H3267017218"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Sorin Pislaru, MD, PhD, who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges William H Gaasch, MD (deceased), who contributed to earlier versions of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43:561.</a></li><li><a class="nounderline abstract_t">Bergler-Klein J, Gyöngyösi M, Maurer G. The role of biomarkers in valvular heart disease: focus on natriuretic peptides. Can J Cardiol 2014; 30:1027.</a></li><li><a class="nounderline abstract_t">Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005; 111:2391.</a></li><li><a class="nounderline abstract_t">Magne J, Mahjoub H, Pierard LA, et al. Prognostic importance of brain natriuretic peptide and left ventricular longitudinal function in asymptomatic degenerative mitral regurgitation. Heart 2012; 98:584.</a></li><li><a class="nounderline abstract_t">Hwang IC, Kim YJ, Kim KH, et al. Prognostic value of B-type natriuretic peptide in patients with chronic mitral regurgitation undergoing surgery: mid-term follow-up results. Eur J Cardiothorac Surg 2013; 43:e1.</a></li><li><a class="nounderline abstract_t">Perreas K, Samanidis G, Dimitriou S, et al. NT-proBNP in the mitral valve surgery. Crit Pathw Cardiol 2014; 13:55.</a></li><li><a class="nounderline abstract_t">Leung DY, Griffin BP, Stewart WJ, et al. Left ventricular function after valve repair for chronic mitral regurgitation: predictive value of preoperative assessment of contractile reserve by exercise echocardiography. J Am Coll Cardiol 1996; 28:1198.</a></li><li><a class="nounderline abstract_t">Magne J, Lancellotti P, Piérard LA. Exercise-induced changes in degenerative mitral regurgitation. J Am Coll Cardiol 2010; 56:300.</a></li><li><a class="nounderline abstract_t">Magne J, Lancellotti P, Piérard LA. Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation 2010; 122:33.</a></li><li><a class="nounderline abstract_t">Donal E, Mascle S, Brunet A, et al. Prediction of left ventricular ejection fraction 6 months after surgical correction of organic mitral regurgitation: the value of exercise echocardiography and deformation imaging. Eur Heart J Cardiovasc Imaging 2012; 13:922.</a></li><li><a class="nounderline abstract_t">Lin SS, Lauer MS, Asher CR, et al. Prediction of coronary artery disease in patients undergoing operations for mitral valve degeneration. J Thorac Cardiovasc Surg 2001; 121:894.</a></li><li><a class="nounderline abstract_t">Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation 1994; 90:830.</a></li><li><a class="nounderline abstract_t">Starling MR, Kirsh MM, Montgomery DG, Gross MD. Impaired left ventricular contractile function in patients with long-term mitral regurgitation and normal ejection fraction. J Am Coll Cardiol 1993; 22:239.</a></li><li><a class="nounderline abstract_t">Ahmed MI, Aban I, Lloyd SG, et al. A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol 2012; 60:833.</a></li><li><a class="nounderline abstract_t">Varadarajan P, Joshi N, Appel D, et al. Effect of Beta-blocker therapy on survival in patients with severe mitral regurgitation and normal left ventricular ejection fraction. Am J Cardiol 2008; 102:611.</a></li><li><a class="nounderline abstract_t">Bonow RO, Nishimura RA, Thompson PD, Udelson JE. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2385.</a></li></ol></div><div id="topicVersionRevision">Topic 8132 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34453165" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2021 ESC/EACTS Guidelines for the management of valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25151285" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The role of biomarkers in valvular heart disease: focus on natriuretic peptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883225" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22342982" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prognostic importance of brain natriuretic peptide and left ventricular longitudinal function in asymptomatic degenerative mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22997191" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic value of B-type natriuretic peptide in patients with chronic mitral regurgitation undergoing surgery: mid-term follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827881" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : NT-proBNP in the mitral valve surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8890816" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Left ventricular function after valve repair for chronic mitral regurgitation: predictive value of preoperative assessment of contractile reserve by exercise echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633822" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Exercise-induced changes in degenerative mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566950" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504944" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prediction of left ventricular ejection fraction 6 months after surgical correction of organic mitral regurgitation: the value of exercise echocardiography and deformation imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11326232" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prediction of coronary artery disease in patients undergoing operations for mitral valve degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044955" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8509547" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impaired left ventricular contractile function in patients with long-term mitral regurgitation and normal ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22818065" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721522" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of Beta-blocker therapy on survival in patients with severe mitral regurgitation and normal left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542667" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
